Research Grade Trebananib|Trebananib（研究用级别）(靶标：Trebananib融合蛋白)
- 货号：RB9THT073096
- 价格：面议
- 点击：578
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Human |
| 抗体亚型 | Fusion - IGHG1 Fc (Fragment constant) - [peptide 1 |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 2.21mg/ml |
| 内毒素水平 | Please contact the lab for this information. |
| 应用 | ELISA, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | ANG-2, ANGPT2, Angiopoietin-2 |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 表达系统 | Mammalian Cells |
| 登录号 | O15123 |
| 背景信息 | Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity. • Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology., PMID:31108880 • Acute respiratory distress syndrome., PMID:30872586 • Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials., PMID:38158159 • Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials., PMID:35085502 • Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials., PMID:38280653 • TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2., PMID:38382813 • Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial., PMID:30905643 • Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials., PMID:35085503 • Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis., PMID:38775153 • Loss of TGFβ-Mediated Repression of Angiopoietin-2 in Pericytes Underlies Germinal Matrix Hemorrhage Pathogenesis., PMID:39129597 |
| 别名 | 2xCon4C, AMG386 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品:
